Sign in
Active, not recruitingNo phase

Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control

Key facts

Who runs it
Zhongshan Ophthalmic Center, Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
200 people, planned
Started
1 Nov 2024
Expected to end
30 Mar 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Blue star MAX-5 spectacle lens
  • Single-vision spectacle lens
Record updated
12 March 2026

Who can take part

Age
8 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 8 to 11 years
  • Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -6.00 to -0.50 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.50 D
  • Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
  • The intraocular pressure of 10 to 21mmHg
  • Volunteer to participate in this clinical trial with signature of the informed consent form

Who cannot take part

  • Participation of the drug clinical trial within three month and the device clinical trial within one month
  • Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursingproducts), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
  • History of eye injury or intraocular surgery
  • Ocular disease, such as uveitis and other inflammatory diseases, glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
  • Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
  • Clinically abnormal slit-lamp findings
  • Abnormal fundus examination
  • Only one eye meets the inclusion criteria
  • Unable to have regular follow-up

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this randomised controlled clinical trial is to compare the effects of a new type of concentric columnar microstructure lens and single-vision spectacle lenses on myopia progression in Chinese children aged 8-11 years with refractive error ranging from -0.50D to -6.00D. Participants will wear spectacles and receive follow-up examinations every half year.

The 2 groups in the trial

  • InterventionTreatment being tested

    Blue star MAX-5 spectacle lens

    Treatment: Blue star MAX-5 spectacle lens

  • ControlExisting treatment, for comparison

    Single-vision spectacle lens

    Treatment: Single-vision spectacle lens

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of Blue Star MAX-5 Lenses in Mvopia Control: A Randomized Controlled Clinical Trial
Record updated
12 March 2026